First the anti-viral Remdesivir with hydroxychloroquine? Now the anti-retroviral Keletra? Each alone, maybe not too good, but apparently very effective in combination. Most promising
……. In a secret trial that was held, they were all given HIV medication, Kaletra and Malaria treatment hydroxychloroquine. The tests were truly successful that these drugs will now be rolled out to COVID-19 patients in at least 50 hospitals nationwide.
The drugs were very much effective
Scientists and researchers started to operate a secret trial on the group of patients who have all now completely recovered.
According to DailyMail, the Consultant Infectious Diseases Physician at the Royal Brisbane and Women’s and Hospital Clinical Research Director, Professor David Paterson of the University of Queensland Centre, have said that “These medications have the potential to be a real cure for all, unlike the random anecdotal experiences of some people.”
Paterson also said that the 50 hospitals will definitely try to resolve the best way to use these drugs and that this would involve comparing the two drugs separately and versus the combination of both.
On the same statement, Paterson reassures everyone that they are ready to go and quickly begin signing up patients into their trial, though this would only happen by the end of the month. The trial will then enable Paterson and his team to test the first wave of Australian patients.
These two drugs can be given orally as tablets
The federal government has already set aside $13 million for researchers to speed up potential treatments. These can be tested up o 10 treatments and with success, it will go directly through the regulatory approval process.
In France, they have begun using malaria drugs hydroxychloroquine in a small trial. Results only show 25% of tested patients treated with the drug still showed signs of the virus compared to a whopping 90% who did not use the drug.
In China, the active drugs in Kaletra, Lopinavir, and ritonavir, have already been tested in at least 199 patients with positive cases and found disappointing results. A published study in the New England Journal of Medicine on March 18 stated that the Chinese researchers gave 99 patients these drugs and the remaining had started care for more than four weeks.
The study concluded that hospitalized adult patients with severe cases had no benefit whatsoever with the drugs. This took 16 days for clinical improvements to arise. Although, the study did find that Kaletra spent the least time in intensive care….